In 2008, mesenchymal stem cells were not gracing the front page of prestigious academic journals as they do today. Yet the founders of Regeneus knew differently. A company
As stem cell therapies move through clinical trials and get closer to the clinic, they are giving rise to new challenges, primarily around costs and the likelihood of
From Biotech Daily, Friday February 9, 2018 By Tim Boreham ASX code: CYP Share price: 82 cents; Shares on issue: 90,057,248 Market cap: $73.8 million Chief executive officer: Dr
A leading Australian stem and regenerative medicine company, Cynata Therapeutics was established with the objective of developing therapeutic products using the Cymerus™ technology. With innovative research, translation and
Despite Australia’s reliable and robust regulatory environment addressing drugs and medical technologies in market, unproven and expensive stem cell therapies have been able to expand and flourish across
MTPConnect – the Medical Technologies and Pharmaceuticals Industry Growth Centre – announced it will provide a proposed $780,000 provisional funding for CCRM Australia over two years, with matched
